Biological Markers and Schizophrenia

Australian and New Zealand Journal of Psychiatry

Volumn 34, Issue , 2000, Pages S108-S112

  Copolov, David ^a   Crook, Jeremy ^b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

biological markers; dopamine; homovanillic acid; review; schizophrenia; smooth pursuit eye movements; ventricles

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE; DOPAMINE 2 RECEPTOR;

BRAIN VENTRICLE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SMOOTH PURSUIT EYE MOVEMENT;

BIOLOGICAL MARKERS; CEREBRAL VENTRICLES; DOPAMINE; HUMANS; MAGNETIC RESONANCE IMAGING; PURSUIT, SMOOTH; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034321753     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/000486700230     Document Type: Article

References (47)

1. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352:1611-1616.
2. Kendell RE. The choice of diagnostic criteria for biological research. Archives of General Psychiatry 1982; 39:1334-1339.
3. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. British Journal of Psychiatry 1998; 172:110-120.
4. Raz S, Raz N. Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imaging. Psychology Bulletin 1990; 108:93-108.
5. Andreasen NC, Swayze VW, Flaum M, Yates WR, Arndt S, McChesney C. Ventricular enlargement in schizophrenia evaluated with computer tomographic scanning. Effects of gender, age, and stage of illness. Archives of General Psychiatry 1990; 47:1008-1015.
6. Roy PD, Zipursky RB, Saint-Cyr JA, Bury A, Langevin R, Seeman MV. Temporal horn enlargement is present in schizophrenia and bipolar disorder. Biological Psychiatry 1998; 44:418-422.
7. Jones PB, Harvey I, Lewis SW et al. Cerebral ventricle dimensions as risk factors for schizophrenia and affective psychosis: an epidemiological approach to analysis. Psychological Medicine 1994; 24:995-1011.
8. Harvey I, McGuffin P, Williams M, Toone BK. The Ventricle-brain ratio (vbr) in functional psychoses. An admixture analysis. Psychiatry Research: Neuroimaging 1989; 35:61-69.
9. Daniel DG, Goldberg TE, Gibbons RD, Weinberger DR. Lack of a bimodal distribution of ventricular size in schizophrenia: a Gaussian mixture analysis of 1056 cases and controls. Biological Psychiatry 1991; 30: 887-903.
10. Suddath RL, George MD, Christison GW, Torrey EF, Casanova MF, Weinberger DR. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. New England Journal of Medicine 1990; 322:789-794.
11. Sharma T, Lancaster E, Lee D et al. Brain changes in schizophrenia. Volumetric MRI study of families multiply affected with schizophrenia - The Maudsley Family Study 5. British Journal of Psychiatry 1998; 173:132-138.
12. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry 1999; 46:729-739.
13. Knoll IV, Garver DL, Ramber JE, Kingsbury SJ, Croissant D, McDermott B. Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Schizophrenia Bulletin 1998; 24:365-379.
14. Lieberman JA, Alvir JM, Koreen PHA et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996; 14: 13-21.
15. Laruelle M. Imaging dopamine transmission in schizophrenia. Quarterly Journal of Nuclear Medicine 1998; 42:211-221.
16. Wong DF, Wagner HN, Tune LE et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naïve schizophrenia. Science 1986; 234:1558-1563.
17. Crawley JC, Owens DG, Crow TJ et al. Dopamine D2 receptors in schizophrenia studied in vivo. Lancet 1986; 2:224-225.
18. Farde L, Wiesel FA, Stone-Elander S et al. D2 dopamine receptors in neuroleptic-naïve schizophrenic patients. Archives of General Psychiatry 1990; 47:213-219.
19. Nordstram AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2 and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. American Journal of Psychiatry 1995; 152:1444-1449.
20. Nyburg S, Nilsson U, Okubo Y, Halldin C, Farde L. Implications of brain imaging for the management of schizophrenia. International Clinical Psychopharmacology 1998; 13: 15-20.
21. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry 1999; 156:286-293.
22. Laruelle M, Abi-Dargham A, van Dyck CH et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Science USA 1996; 99:9235-9240.
23. Abi-Dargham A, Gil R, Krystal J et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. American Journal of Psychiatry 1998; 155:761-767.
24. Tuckwell HC, Koziol JA. A meta-analysis of homovanillic acid concentrations in schizophrenia. International Journal of Neuroscience 1993; 73:109-114.
25. Copolov DL, Keks NA, Kulkarni J et al. Prolactin response to low-dose halperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. Psychoneuroendocrinology 1990; 15:225-231.
26. Keks NA, McKenzie DP, Low LH et al. Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients. Biological Psychiatry 1992; 32:426-437.
27. Wieselgren IM, Lindstrom LH. CSF levels of HVA and 5-HIAA in drug free schizophrenic patients and healthy controls: a prospective study focussed on their predictive value for outcome in schizophrenia. Psychiatry Research 1998; 81:101-110.
28. Bowers MB. Lumber CSG 5-hydroxyindoleacetic acid and homovanillic acid in affective syndromes. Journal of Nervous and Mental Disease 1974; 158:325-330.
29. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and health controls. British Journal of Psychiatry 1985; 147:276-282.
30. Lindstrom LH. Low HVA and normal 5-HIAA CSF levels in drug-free schizophrenic patients compared to health volunteers: correlations to symptomatology and family history. Psychiatry Research 1985; 14:265-273.
31. Maas JW, Bowden CL, Miller AL et al. Schizophrenia, psychosis and cerebral spinal fluid homovanillic acid concentrations. Schizophrenia Bulletin 1997; 23:147-154.
32. Gomes UCR, Shanley BC, Potgieter L, Roux JT. Noradrenergic overactivity in chronic schizophrenia: evidence based cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations. British Journal of Psychiatry 1980; 137:346-351.
33. Gerner RH, Fairbanks L, Anderson GM et al. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. American Journal of Psychiatry 1984; 141:1533-1540.
34. Pickar D, Breier A, Hsiao JK et al. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychoses. Archives of General Psychiatry 1990; 47:641-648.
35. Kirch DG, Suddath RL, Gerhardt GA, Issa F, Freedman R, Wyatt RL. Analysis of cerebrospinal fluid monoamines in schizophrenic patients on and off neuroleptic treatment and compared with health controls. Schizophrenia Research 1991; 4:349.
36. Maas JW, Contreras SA, Miller AL et al. Studies of catecholamine metabolism in schizophrenia/psychosis-I. Neuropsychopharmacology 1993; 8:97-109.
37. Davidson M, David KL. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Archives of General Psychiatry 1988; 45:561-563.
38. Nagaoka S, Iwamoto N, Arai H. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biological Psychiatry 1997; 41:857-864.
39. Amin F, Davidson M, Davis KL. Homovanillic acid measurement in clinical research: a review of methodology. Schizophrenia Bulletin 1992; 18:123-148.
40. Hutton S, Kennard C. Oculomotor abnormalities in schizophrenia: a critical review. Neurology 1998; 50:604-609.
41. Thaker GK, Kirkpatrick B, Buchanan RW, Ellsberry R, Lahti A, Tamminga C. Oculomotor abnormalities and their clinical correlates in schizophrenia. Psychopharmacology Bulletin 1989; 25:491-497.
42. King DJ. Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatrica Scandinavica 1994; 380:53-58.
43. Holzman PS, Proctor LR, Levy DL, Yasillo NJ, Meltzer HY, Hurt SW. Eye-tracking dysfunctions in schizophrenic patients and their relatives. Archives of General Psychiatry 1974; 31:143-151.
44. Lencer R, Malchow CP, Trillenberg-Krecker K, Schwinger E, Arolt V. Eye-tracking dysfunction (ETD) in families with sporadic and familial schizophrenia. Biological Psychiatry 2000; 47:391-401.
45. Arolt V, Lencer R, Nolte A et al. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosone 6p in families with multiple occurrence of the disease. American Journal of Medicine Genetics 1996; 67:564-579.
46. Freedman R, Adler LE, Leonard S. Alternative phenotypes for the complex genetics of schizophrenia. Biological Psychiatry 1999; 45:551-558.
47. Steinlein OK, Mulley JC, Propping P et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nature Genetics 1995; 11:201-203.